Cardiol Therapeutics Inc
Company Profile
Business description
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
Contact
2265 Upper Middle Road East
Suite 602
OakvilleONL6H 0G5
CANT: +1 289 910-0850
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
18
Stocks News & Analysis
stocks
ASX retail share remains cheap despite weaker earnings
stocks
AI isn’t an economic moat killer, but it will disrupt industries
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,726.50 | 32.00 | -0.37% |
| CAC 40 | 7,769.31 | 77.24 | -0.98% |
| DAX 40 | 22,612.97 | 344.11 | -1.50% |
| Dow JONES (US) | 45,960.11 | 469.38 | -1.01% |
| FTSE 100 | 9,972.17 | 134.67 | -1.33% |
| HKSE | 24,856.43 | 479.52 | -1.89% |
| NASDAQ | 21,408.08 | 521.74 | -2.38% |
| Nikkei 225 | 53,603.65 | 145.97 | -0.27% |
| NZX 50 Index | 12,979.52 | 2.53 | 0.02% |
| S&P 500 | 6,477.16 | 114.74 | -1.74% |
| S&P/ASX 200 | 8,525.70 | 21.30 | -0.25% |
| SSE Composite Index | 3,889.08 | 42.75 | -1.09% |